Doxorubicin is one of the leading drugs for osteosarcoma standard chemotherapy. A total of 40% to 45% of high-grade osteosarcoma patients are unresponsive, or only partially responsive, to doxorubicin (Dox), due to the overexpression of the drug efflux transporter ABCB1/P-glycoprotein (Pgp). The aim of this work is to improve Dox-based regimens in resistant osteosarcomas. We used a chemically modified mitochondria-targeted Dox (mtDox) against Pgp-overexpressing osteosarcomas with increased resistance to Dox. Unlike Dox, mtDox accumulated at significant levels intracellularly, exerted cytotoxic activity, and induced necrotic and immunogenic cell death in Dox-resistant/Pgp-overexpressing cells, fully reproducing the activities exerted by anthracyclines in drug-sensitive tumors. mtDox reduced tumor growth and cell proliferation, increased apoptosis, primed tumor cells for recognition by the host immune system, and was less cardiotoxic than Dox in preclinical models of drug-resistant osteosarcoma. The increase in Dox resistance was paralleled by a progressive upregulation of mitochondrial metabolism. By widely modulating the expression of mitochondria-related genes, mtDox decreased mitochondrial biogenesis, the import of proteins and metabolites within mitochondria, mitochondrial metabolism, and the synthesis of ATP. These events were paralleled by increased reactive oxygen species production, mitochondrial depolarization, and mitochondria-dependent apoptosis in resistant osteosarcoma cells, where Dox was completely ineffective. We propose mtDox as a new effective agent with a safer toxicity profile compared with Dox that may be effective for the treatment of Dox-resistant/Pgp-positive osteosarcoma patients, who strongly need alternative and innovative treatment strategies. Mol Cancer Ther; 15(11); 2640-52. ©2016 AACR.

Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma

BUONDONNO, ILARIA;GAZZANO, Elena;AUDRITO, VALENTINA;KOPECKA, JOANNA;SALAROGLIO, IRIS CHIARA;COSTAMAGNA, Costanzo;ROATO, ILARIA;MUNGO, ELEONORA;DEAGLIO, Silvia;RIGANTI, Chiara
Last
2016-01-01

Abstract

Doxorubicin is one of the leading drugs for osteosarcoma standard chemotherapy. A total of 40% to 45% of high-grade osteosarcoma patients are unresponsive, or only partially responsive, to doxorubicin (Dox), due to the overexpression of the drug efflux transporter ABCB1/P-glycoprotein (Pgp). The aim of this work is to improve Dox-based regimens in resistant osteosarcomas. We used a chemically modified mitochondria-targeted Dox (mtDox) against Pgp-overexpressing osteosarcomas with increased resistance to Dox. Unlike Dox, mtDox accumulated at significant levels intracellularly, exerted cytotoxic activity, and induced necrotic and immunogenic cell death in Dox-resistant/Pgp-overexpressing cells, fully reproducing the activities exerted by anthracyclines in drug-sensitive tumors. mtDox reduced tumor growth and cell proliferation, increased apoptosis, primed tumor cells for recognition by the host immune system, and was less cardiotoxic than Dox in preclinical models of drug-resistant osteosarcoma. The increase in Dox resistance was paralleled by a progressive upregulation of mitochondrial metabolism. By widely modulating the expression of mitochondria-related genes, mtDox decreased mitochondrial biogenesis, the import of proteins and metabolites within mitochondria, mitochondrial metabolism, and the synthesis of ATP. These events were paralleled by increased reactive oxygen species production, mitochondrial depolarization, and mitochondria-dependent apoptosis in resistant osteosarcoma cells, where Dox was completely ineffective. We propose mtDox as a new effective agent with a safer toxicity profile compared with Dox that may be effective for the treatment of Dox-resistant/Pgp-positive osteosarcoma patients, who strongly need alternative and innovative treatment strategies. Mol Cancer Ther; 15(11); 2640-52. ©2016 AACR.
2016
15
11
2640
2652
P-glycoprotein; osteosarcoma; doxorubicin; chemoresistance; mitochondria
Buondonno, Ilaria; Gazzano, Elena; Jean, Sae Rin; Audrito, Valentina; Kopecka, Joanna; Fanelli, Marilù; Salaroglio, Iris C; Costamagna, Costanzo; Roato, Ilaria; Mungo, Eleonora; Hattinger, Claudia M; Deaglio, Silvia; Kelley, Shana O; Serra, Massimo; Riganti, Chiara
File in questo prodotto:
File Dimensione Formato  
Buondonno MCT MS and Supplementray 2016.pdf

Accesso riservato

Descrizione: Buondonno, MS and supplemnetary pdf editoriale MCT, 2016
Dimensione 3.22 MB
Formato Adobe PDF
3.22 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Buondonno, AOP Mol Cancer Ther MS and Supplementary, 2016.pdf

Open Access dal 01/12/2017

Descrizione: Buondonno, MS and supplemnetary Open Access MCT, 2016
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 15.98 MB
Formato Adobe PDF
15.98 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1610727
Citazioni
  • ???jsp.display-item.citation.pmc??? 41
  • Scopus 79
  • ???jsp.display-item.citation.isi??? 72
social impact